Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1451 - 1475 of 2306 in total
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
AR-9281 inhibits soluble epoxide hydrolase.
Investigational
WNT974 has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.
Investigational
Axt914 is under investigation in clinical trial NCT00417261 (Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.).
Investigational
Experimental
NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
Investigational
GS-9256 has been used in trials studying the treatment of HCV Infection and Chronic Hepatitis C Infection.
Investigational
Investigational
Investigational
Investigational
Carbomer homopolymer type C is a high molecular polyanionic substance tested for antiulcerogenic activity.
Experimental
Investigational
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of …
Experimental
Investigational
Matched Products: … URFAMYCİN SÜSPANSİYON HAZIRLAMAK İÇİN KURU TOZ, 60 ML …
Experimental
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
Investigational
TO-901317 is an LXRalpha and LXRbeta agonist.
Experimental
Experimental
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase …
Experimental
Experimental
Experimental
Displaying drugs 1451 - 1475 of 2306 in total